Kahalalide F and ES285: Potent Anticancer Agents from Marine Molluscs
The marine environment is proving to be a very rich source of unique compounds with significant activities against cancer of several types. Finding the sources of these new chemical entities has made it necessary for marine and medical scientists to find enterprising ways to collaborate in order to sample the great variety of intertidal, shallow and deep-water sea life. Recently these efforts resulted in a first generation of drugs from the sea undergoing clinical trials. These include PharmaMar compounds: Yondelis, Aplidin, kahalalide F, ES285 and Zalypsis. Two of these compounds, kahalalide F and ES285, have been isolated from the Indopacific mollusc Elysia rufescens and the North Atlantic mollusc Spisula polynyma, respectively.
Unable to display preview. Download preview PDF.
- Ciruelos C, Trigo J, Pardo J, Paz-Ares L, Estaun N, Cuadra C, Domínguez M, Marín A, Jimeno JM, Izquierdo M (2002) A phase I clinical and pharmacokinetic study with Kahalalide F in patients with advanced solid tumours with a continuous weekly 1-hour iv infusion schedule. Eur J Cancer 38:33CrossRefGoogle Scholar
- Córdoba S, Zapata I, Romero J, de la Torre A, López-Martin JA, Vargas JA, Sánchez-Prieto R, Corbacho C, Regueiro CA, Magallón R (2003) In vitro chemosensitivity, cell cycle redistribution and apoptosis induction by Kahalalide F, a new marine compound in a panel of human tumoural cells. Eur J Cancer Suppl 1:S173CrossRefGoogle Scholar
- Gajate C, An F, Nieto-Miguel T, Mollinedo F (2005) Induction of apoptosis by the novel marine-derived antitumour agent ES-285 (spisulosine): cell cycle arrest, and mitochondrial and caspase involvement (in press)Google Scholar
- <AQ. Please update Gajate et al. (2005).>Google Scholar
- Green BJ, Li W, Manhart JR, Fox TC, Summer EJ, Kennedy RA, Pierce SK, Rumpho ME (2000) Mollusc–algal chloroplast endosymbiosis. Photosynthesis, thylakoid protein maintenance, and chloroplast gene expression continue for many months in the absence of the algal nucleus. Plant Physiol 124:331–342PubMedCrossRefGoogle Scholar
- Janmaat ML, Kruyt FAE, Jimeno J, Rodríguez JA, Giaccone G (2004) Kahalalide F induces caspase-independent cytotoxicity that correlates with HER2 and/or HER3 expression levels and is accompanied by down-regulation of AKT signaling. Proc AACR 95:5328Google Scholar
- Lacal JC, Rodríguez-González A, Alvarez-Miranda M (2004) Study of the mechanism of action of ES285. PharmaMar, MadridGoogle Scholar
- Rinehart KL, Fregeau NL, Warwick RA (1998) US patent 6107520cGoogle Scholar
- Salcedo M (2005) The marine antitumour compound ES 285 activates EGD receptors and PKC, and in parallel triggers an atypical cell death pathway (in press)Google Scholar
- Salcedo M, Cuevas C, Sánchez-Puelles JM, Otero G, Sousa JM, Avila J, Wandosell F (2003) Proc Am Assoc Cancer Res 44:3649Google Scholar
- Schellens JH, Rademaker JL, Horenblas S, Meinhardt W, Stukvis E, de Reijke TM, Jimeno JM, López-Lazaro L, López-Martín JA, Beijnen JH (2002) Phase I and pharmacokinetic study of Kahalalide F in patients with advanced androgen refractory prostate cancer. Proc ASCO 38:451Google Scholar
- Sewell JM, Langdon SP, Smyth JF, Jodrell I, Guichard S (2004) Kahalalide F appears to promote necrotic cell death in hepatoma cell lines. Proc AACR 95:1509Google Scholar